SCHEMBL30748898

SCHEMBL30748898

CC(C)(O)c1cnc(CO)nc1Nc1ccc(Oc2ccccc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.41
KDR P35968 2/20 0.41
TEK Q02763 1/20 0.41
RIPK2 O43353 1/20 0.41
EPHB2 P29323 1/20 0.41
STK17A Q9UEE5 2/20 0.40
BCDIN3D Q7Z5W3 1/20 0.39
GAA P10253 2/20 0.39
TTBK1 Q5TCY1 1/20 0.39
TTBK2 Q6IQ55 1/20 0.39
MAP2K1 Q02750 1/20 0.38
SCN5A Q14524 1/20 0.38
SCN9A Q15858 1/20 0.38
PIN1 Q13526 1/20 0.38
BTK Q06187 1/20 0.38
PDK1 Q15118 1/20 0.38
PDK2 Q15119 1/20 0.38
PDK3 Q15120 1/20 0.38
PDK4 Q16654 1/20 0.38
STK17B O94768 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31691219 0.85 EGFR (0.37) EGFRKDRTEKRIPK2EPHB2
SCHEMBL30749000 0.83 KDR (0.42) EGFRKDRTEKRIPK2EPHB2
SCHEMBL30749018 0.78 SYK (0.40) EGFRKDRTEKRIPK2EPHB2
SCHEMBL30748748 0.78 MAP2K1 (0.56) KDRMAP2K1PIN1
SCHEMBL30749039 0.71 HTR2C (0.49) EGFRKDRTEKTTBK1TTBK2
SCHEMBL30748772 0.71 PDE10A (0.44) KDRTEKTTBK1TTBK2MAP2K1
SCHEMBL30748744 0.71 ERBB2 (0.50) KDRTEKSCN5ASCN9AERBB2
SCHEMBL14771970 0.71 STK17A (0.53) EGFRKDRTEKRIPK2EPHB2
SCHEMBL30748961 0.69 TTBK1 (0.60) EGFRTTBK1TTBK2
SCHEMBL28142602 0.66 LTA4H (0.58) EGFRKDRTEKRIPK2EPHB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT EGFR 2829/4885KDR 4605/4885TEK 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.